$OSTX News

Last published 1mo ago

1mo agoOSTXRubenstein Public Relations Named Agency of Record for OS TherapiesGlobeNewswireNEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rubenstein Public Relations (RPR), a leading full-service communications firm, announces it has been named the Agency of Record for OS Therapies, Inc. (NYSE:OSTX), the
1y agoOSTXOS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic OsteosarcomaBusiness WireCompany will be seeking alignment to begin rolling BLA submission OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical
1y agoOSTXOS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma ConferenceBusiness WireThe primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control (20%) Company
1y agoONCY TEVA CTOR ADCT+1The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?PR NewswireUSA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in...
1y agoOSTXOS Therapies Announces Warrant Exercise Inducement & Exchange OfferBusiness WireCurrent holders of five-year warrants with a current exercise price of $1.12 per share issued in connection with PIPE transaction initially closed on December 31, 2024 ("Old Warrants") offered opportunity to exercise
1y agoOSTXOS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic OsteosarcomaPR NewswireOS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology...
1y agoOSTXOS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric OsteosarcomaBusiness WireIf awarded, OST-HER2 would become the first listeria investigational medicinal product to be awarded the RMAT designation RMAT designation reduces BLA application review time and permits augmented interactions with
1y agoOSTXOS Therapies Reports First Quarter 2025 Financial Results and Provides Business UpdateBusiness WireFeedback from Type D FDA Meeting expected by mid-June 2025 to confirm statistical analysis methods to support pending Accelerated Approval, Regenerative Medicine Advanced Therapy & Breakthrough Therapy designation
1y agoOSTXOS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine OsteosarcomaBusiness WireOS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the launch of OS Animal Health, Inc., a wholly
1y agoOSTXOS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040Business WirePhase 3-stage OST-AXIL for HPV, Phase 2-stage OST-503 for NSCLC & GBM and Phase 1-stage OST-504 for Prostate cancer also covered under patent Eight (8) pre-clinical additional immunotherapy candidates also
1y agoOSTXEmmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer TherapiesBusiness WireOfficial trailer is now live at https://youtu.be/pFaockwrROM The official trailer for "Shelter Me: The Cancer Pioneers" has just dropped, giving audiences a moving first look at the groundbreaking new documentary that
1y agoOSTXOS Therapies FDA Meeting Request GrantedBusiness WireWritten response-only meeting to align analysis plan of surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung
1y agoONCY CVM OSTX ONC+1With Young Adult Cancer on the Rise, New Therapies Spark Investor BuzzPR NewswireEquity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...
1y agoOSTXOS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in HumansBusiness WireYet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, delayed pulmonary
1y agoOSTXOS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala PharmaceuticalsBusiness WireCompany now listeria-based cancer immunotherapy world leader Expands clinical pipeline with 3 new cancer immunotherapy candidates 8 pre-clinical immunotherapy candidates targeting 30+ cancers added OS Therapies
1y agoOSTXOS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic OsteosarcomaBusiness WireOS Therapies applies for meeting per FDA suggestion received on April 2, 2025 Based on prior FDA guidance, greater than 200 suitable matched lung metastatic osteosarcoma patient records identified from leading
1y agoOSTXOS Therapies to Host Analyst Day at NYSE on April 7, 2025Business WireOS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the Company will be hosting an Analyst Day
1y agoOSTXOS Therapies Reports Full Year 2024 Financial Results and Provides Business UpdateBusiness WireFull data from OST-HER2 Phase 2b osteosarcoma trial, including synthetic control arm data being developed at the request of FDA to support a Breakthrough Therapy Designation request, to be presented at MIB Factor in
1y agoOSTXOS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human OsteosarcomaBusiness WireDialogue open with FDA in preparation for End of Phase 2 Meeting request New canine elite responder biomarkers added to human biomarker strategy OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a
1y agoOSTXOS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer PioneersBusiness WireDocumentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and
1y agoOSTXOS Therapies to Attend The Jones Healthcare and Technology Innovation ConferenceBusiness WireOS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and Gerald Commissiong,
1y agoOSTXOS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma ConferenceBusiness WireOS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the
1y agoOSTXOS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for OsteosarcomaBusiness WireOS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting
1y agoCLDI OSTXCalidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVACCESS NewswireORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. and OS Therapies Inc. on the RedChip Small Stocks, Big Money™
1y agoOSTXJoin OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27Business WireOS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar on February 27, 2025, at 4:15
1y agoOSTXOS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates PlatformsBusiness WireOS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The
1y agoOSTXOS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2Business WirePatent Term Adjustment will provide market exclusivity in the United States into 2040 for all therapeutic indications OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing
1y agoOSTXOS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) FilingBusiness WireOS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the
1y agoOSTXOS Therapies Provides Corporate UpdateBusiness WireStrong cash position relative to monthly burn and cash needs into mid-2026 Significant regulatory milestones upcoming in OST-HER2 osteosarcoma program Pending acquisition paves the way for commercialization and
1y agoBFRG CNTM GRRR OSTX+1RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock AnalysisACCESS NewswireRedChat provides data-driven precision, real-time efficiency, and comprehensive coverage ORLANDO, FL / ACCESS Newswire / February 3, 2025 / RedChip Companies, an industry leader in investor relations, media, and research
1y agoOSTXOS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic OsteosarcomaBusiness WireThe primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (33.3%) was statistically significant (p= 0.0158) when compared with peer-reviewed comparable historical control
1y agoOSTXOS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness WireCEO Paul Romness available to meet with institutional investors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment,
1y agoOSTXOS Therapies Announces Closing of $6 Million Private PlacementBusiness WireFunding expected to provide cash runway into 2026 98% of investment in private placement from Pre-IPO and/or IPO investors Data update from OST-HER2 Phase 2b clinical trial in recurrent, resected metastatic
1y agoOSTXOS Therapies Partners with B2i Digital to Engage with Biotech Investors OnlineBusiness WireDigital Marketing Campaign to Highlight Clinical-Stage Cancer Innovation OST-HER2 that activates cellular immunity against HER2+ cancer OS Therapies Joins the B2i Digital Featured Companies Program OS Therapies,
1y agoOSTXOS Therapies Announces Pricing of $6 Million Private PlacementBusiness WireFunding will provide Company sufficient cash runway into 2026 95% of investment in private placement from Pre-IPO and/or IPO investors Data from OST-HER2 Phase 2b in recurrent, resected metastatic osteosarcoma to
1y agoOSTXOS Therapies Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness WireTopline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer
2y agoOSTXOS Therapies to Present at The Spartan Capital Investor ConferenceBusiness WireOS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief Executive Officer, and
2y agoOSTXJoin OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30Business WireOS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to a webinar on October 30, 2024, at
2y agoBMY DRIO NVS OSTX+1OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of DirectorsBusiness WireConcurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate
2y agoOSTXOS Therapies to Present at the LD Micro Main Event XVIIBusiness WireOS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, and Gerald
2y agoOSTXOS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitBusiness WireOS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, will be
2y agoOSTXOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient VisitBusiness WireCompany to ring Closing Bell at NYSE on Thursday, October 3, 2024 Interviews scheduled with Fintech.TV and Schwab Network OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and
2y agoOSTXOS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic CandidatesBusiness WireFirst therapeutic candidate targets Breast Cancer, Lung Cancer and Gastric Cancer Second therapeutic candidate targets platinum-resistant Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer OS
2y agoOSTXOS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical ModelsACCESS NewswireFolate receptor alpha targeting drug conjugate & hexa silanol exatecan payloads tested in animal models of ovarian cancerStrong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancerStrong safety
2y agoOSTXOS Therapies to Present at H.C. Wainright 26th Annual Global Investment ConferenceBusiness WireOS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced its participation in the H.C. Wainright 26th Annual Global
2y agoOSTXOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment DoseBusiness WireOS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in
2y agoOSTXOS Therapies Appoints Borys Shor, PhD to ADC Advisory BoardBusiness WireOS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has appointed Borys Shor, PhD to its Antibody Drug
2y agoOSTXOS Therapies Clarifies CUSIP of Common StockBusiness WireOS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today provided a clarification for market participants, specifically brokerage
2y agoOSTXOS Therapies Accepted Into Johnson & Johnson Innovation - JLABSBusiness WireFocus of work at JLABS on tunable Antibody Drug Conjugate linker-based platform OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical
2y agoOSTXOS Therapies Reports Second Quarter 2024 Financial ResultsACCESS NewswireSuccessful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financialsConversion of all reported outstanding